Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Denosumab for the treatment of osteoporosis: a systematic literature review.

Silva-Fernández L, Rosario MP, Martínez-López JA, Carmona L, Loza E.

Reumatol Clin. 2013 Jan-Feb;9(1):42-52. doi: 10.1016/j.reuma.2012.06.007. Epub 2012 Sep 1. Review.

2.

Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.

Bridgeman MB, Pathak R.

Clin Ther. 2011 Nov;33(11):1547-59. doi: 10.1016/j.clinthera.2011.10.008. Review.

PMID:
22108301
3.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD005326.

PMID:
16856092
4.

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.

Lin T, Wang C, Cai XZ, Zhao X, Shi MM, Ying ZM, Yuan FZ, Guo C, Yan SG.

Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7. Review.

PMID:
22313934
5.

Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.

Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA; AMG 162 Bone Loss Study Group.

J Bone Miner Res. 2007 Dec;22(12):1832-41.

6.

Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.

von Keyserlingk C, Hopkins R, Anastasilakis A, Toulis K, Goeree R, Tarride JE, Xie F.

Semin Arthritis Rheum. 2011 Oct;41(2):178-86. doi: 10.1016/j.semarthrit.2011.03.005. Epub 2011 May 26.

PMID:
21616520
7.

Denosumab for treatment of postmenopausal osteoporosis.

Chitre M, Shechter D, Grauer A.

Am J Health Syst Pharm. 2011 Aug 1;68(15):1409-18. doi: 10.2146/ajhp100493. Review.

PMID:
21785030
8.

Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.

Migliore A, Broccoli S, Massafra U, Cassol M, Frediani B.

Eur Rev Med Pharmacol Sci. 2013 Mar;17(5):658-67.

9.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.

McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD.

Osteoporos Int. 2013 Jan;24(1):227-35. doi: 10.1007/s00198-012-2052-4. Epub 2012 Jul 10.

10.

Denosumab in postmenopausal women with low bone mineral density.

McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group.

N Engl J Med. 2006 Feb 23;354(8):821-31.

11.

Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis.

Zhou Z, Chen C, Zhang J, Ji X, Liu L, Zhang G, Cao X, Wang P.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2113-22. eCollection 2014. Review.

12.

Effect of osteoporosis treatment on mortality: a meta-analysis.

Bolland MJ, Grey AB, Gamble GD, Reid IR.

J Clin Endocrinol Metab. 2010 Mar;95(3):1174-81. doi: 10.1210/jc.2009-0852. Epub 2010 Jan 15.

PMID:
20080842
13.

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.

McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA.

J Bone Miner Res. 2012 Jul;27(7):1480-6. doi: 10.1002/jbmr.1606.

14.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005326. Review.

PMID:
17054253
15.

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.

Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi JD, Goeree R.

J Med Econ. 2012;15 Suppl 1:3-14. doi: 10.3111/13696998.2012.737393. Epub 2012 Oct 16.

PMID:
23035625
16.

Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review.

Melek J, Sakuraba A.

Clin Gastroenterol Hepatol. 2014 Jan;12(1):32-44.e5. doi: 10.1016/j.cgh.2013.08.024. Epub 2013 Aug 24. Review.

PMID:
23981521
17.

Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.

Josse R, Khan A, Ngui D, Shapiro M.

Curr Med Res Opin. 2013 Mar;29(3):205-16. doi: 10.1185/03007995.2013.763779. Epub 2013 Jan 25. Review. Erratum in: Curr Med Res Opin. 2013 Sep;29(9):1211.

PMID:
23297819
18.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.

J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716.

19.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Wensel TM, Iranikhah MM, Wilborn TW.

Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510. Review.

PMID:
21923432
20.

Interventions for the treatment of decreased bone mineral density associated with HIV infection.

Lin D, Rieder MJ.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005645. Review.

PMID:
17443607

Supplemental Content

Support Center